Get the Stockscreener App
5.82
13.26%
-0.89
After Hours:
5.93
0.11
+1.89%
Solid Biosciences Inc stock is traded at $5.82, with a volume of 2.87M.
It is down -13.26% in the last 24 hours and down -33.10% over the past month.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
See More
Previous Close:
$6.71
Open:
$6.65
24h Volume:
2.87M
Relative Volume:
2.16
Market Cap:
$624.05M
Revenue:
$6.17M
Net Income/Loss:
$-191.78M
P/E Ratio:
-2.99
EPS:
-1.9465
Net Cash Flow:
$-172.86M
1W Performance:
-15.90%
1M Performance:
-33.10%
6M Performance:
-30.63%
1Y Performance:
-3.16%
1-Day Range:
$5.70
$6.65
1-Week Range:
$5.70
$7.045
52-Week Range:
$3.79
$11.45
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.82 | 624.05M | 6.17M | -191.78M | -172.86M | -1.9465 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-26 | Initiated | RBC Capital Mkts | Outperform |
| Aug-21-26 | Resumed | Truist | Buy |
| Mar-20-26 | Initiated | Guggenheim | Buy |
| Dec-04-25 | Initiated | Needham | Buy |
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Form 4 Solid Biosciences LLC For: 11 October By Investing.com - Investing.com Canada
A director converts a stock grant and holds 141,585 Solid Biosciences (SLDB) shares directly. - Stock Titan
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy’s Limitations (NASDAQ:SLDB) - Seeking Alpha
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView
Solid Biosciences (Nasdaq:SLDB)Stock Analysis - Simply Wall Street
Solid Biosciences stock gains on fresh analyst upgrades and DMD outlook - AD HOC NEWS
Solid Biosciences Inc.Common Stock (Nasdaq:SLDB) Detailed Stock Data - The Chronicle-Journal
Solid Biosciences wins new Outperform at RBC on DMD opportunity - Seeking Alpha
Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates - kalkine.com.au
Solid Biosciences at Citi summit: FDA tests loom for gene therapy push - Investing.com Canada
Solid Biosciences at Cantor Fitzgerald conference: 2025 catalyst push By Investing.com - Investing.com India
Solid Biosciences at Cantor Fitzgerald conference: 2025 catalyst push By Investing.com - Investing.com Canada
SLDB: Pivotal gene therapy data and regulatory milestones for DMD and FA expected in early 2025 - TradingView
Solid Biosciences Stock Price Forecast. Should You Buy SLDB? - StockInvest.us
Solid Biosciences Insiders Sell US$823k Of Stock, Possibly Signalling Caution - simplywall.st
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Solid Biosciences to Participate at Upcoming Investor Conferences - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) - The Globe and Mail
Cantor raises Solid Biosciences stock price target on gene therapy - Investing.com
Cantor raises Solid Biosciences stock price target on gene therapy By Investing.com - Investing.com Canada
Cantor raises Solid Biosciences stock price target on gene therapy By Investing.com - Investing.com UK
Cantor Fitzgerald Maintains Solid Biosciences(SLDB.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Solid Biosciences Inc (SLDB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SLDB Maintained by Truist Securities -- Price Target Raised to $20 - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Truist Financial Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $20 - Moomoo
Solid Biosciences (NASDAQ:SLDB) Stock Price Down 6.7%Time to Sell? - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Solid Biosciences Inc. brings patient advocates to FA panel at GMP Lab - Traders Union
Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits - Stock Titan
Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares - Stock Titan
Solid Biosciences (SLDB) Holds Steady Near $9.09 as Gene Therapy Sector Watches Key LevelsVolume Weighted Price - vinanet.vn
HC Wainwright Has Positive Estimate for SLDB Q3 Earnings - MarketBeat
Form 8K Solid Biosciences LLC For: 6 August By Investing.com - Investing.com Nigeria
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Dimensional Fund Advisors LP Acquires 277,051 Shares of Solid Biosciences Inc. $SLDB - MarketBeat
Solid Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citizens reiterates Solid Biosciences stock rating on pipeline progress By Investing.com - Investing.com Nigeria
Citizens reiterates Solid Biosciences stock rating on pipeline progress - Investing.com
Citizens reiterates Solid Biosciences stock rating on pipeline progress By Investing.com - Investing.com South Africa
Citizens reiterates Solid Biosciences stock rating on pipeline progress - Investing.com India
Citizens reiterates Solid Biosciences stock rating on pipeline progress By Investing.com - Investing.com Canada
Citizens reiterates Solid Biosciences stock rating on pipeline progress By Investing.com - Investing.com UK
Citizens reiterates Solid Biosciences stock rating on pipeline progress - Investing.com
Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Solid Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Solid Biosciences Inc. Stock 12‑Month Price Target Cut to $17.64, Implies 102% Upside - TradingView
Solid Biosciences Inc (SLDB) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Solid Biosciences files prospectus for up to $200 million at-the-market stock offering - Bitget
Solid Biosciences (SLDB) Eyes Key Clinical Milestones Amid High Valuation on Price-to-Sales Basis - GuruFocus
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Solid Biosciences Inc Stock (SLDB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hanrahan Jessie | Officer |
Feb 18 '26 |
Proposed Sale |
5.82 |
4,134 |
24,074 |
0 |
| Ganot Ilan | Director |
Feb 18 '26 |
Sale |
5.82 |
2,658 |
15,478 |
27,474 |
| Herzich Paul | Officer |
Feb 18 '26 |
Proposed Sale |
5.82 |
3,616 |
21,057 |
0 |
| Ganot Ilan | Director |
Feb 18 '26 |
Proposed Sale |
5.92 |
2,658 |
15,748 |
0 |
| Brooks Gabriel | Officer |
Feb 18 '26 |
Proposed Sale |
5.82 |
5,563 |
32,395 |
0 |
| Herzich Paul | Chief Technology Officer |
Feb 18 '26 |
Sale |
5.82 |
3,616 |
21,057 |
72,638 |
| Howton David T | Chief Operating Officer |
Feb 18 '26 |
Sale |
5.82 |
7,469 |
43,494 |
105,077 |
| Howton David T | Officer |
Feb 18 '26 |
Proposed Sale |
5.82 |
7,469 |
43,494 |
0 |
| Tan Kevin | Officer |
Feb 18 '26 |
Proposed Sale |
5.82 |
5,404 |
31,469 |
0 |
| Tan Kevin | CFO & Treasurer |
Feb 18 '26 |
Sale |
5.82 |
5,404 |
31,469 |
99,422 |
4.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):